Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
100 hedge funds and large institutions have $284M invested in Provention Bio, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 47 increasing their positions, 28 reducing their positions, and 16 closing their positions.
156% more call options, than puts
Call options by funds: $5.1M | Put options by funds: $1.99M
68% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $294M → $284M (-$10.5M)
6% less funds holding
Funds holding: 106 → 100 (-6)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$11.4M |
| 2 |
Two Sigma Advisers
New York
|
+$6.03M |
| 3 |
BlackRock
New York
|
+$5.41M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$4.8M |
| 5 |
Two Sigma Investments
New York
|
+$4.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$7.22M |
| 2 |
JJIJ
Johnson & Johnson Innovation - JJDC
New Brunswick,
New Jersey
|
-$6.95M |
| 3 |
Millennium Management
New York
|
-$5.87M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.53M |
| 5 |
PA
Perceptive Advisors
New York
|
-$3.28M |
PRVB Hedge Fund Activity: Q3 2020 in Review
100 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2020, worth a combined $284M — down 3.6% from $294M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PRVB and 10 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 47 added.
The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $11.4M. The largest seller was Citigroup, cutting an estimated $7.22M.
- 100 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2020, down from 106 in Q2 2020.
- Funds reported $284M of Provention Bio, Inc. Common Stock stock for Q3 2020, down 3.6% quarter-over-quarter.
- 10 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2020 and 16 closed out, a net change of -6 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q3 2020 was Gilder Gagnon Howe & Co, an estimated $11.4M added.
- The largest Provention Bio, Inc. Common Stock seller in Q3 2020 was Citigroup, an estimated $7.22M sold.
Based on aggregated 13F filings for Q3 2020.